午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

APP抗體,Mouse Monoclonal APP Antibody
  • APP抗體,Mouse Monoclonal APP Antibody
  • APP抗體,Mouse Monoclonal APP Antibody
  • APP抗體,Mouse Monoclonal APP Antibody

APP抗體

價(jià)格 詢價(jià)
包裝 20μl 50μl 100μl
最小起訂量 1μl
發(fā)貨地 湖北
更新日期 2025-05-10
QQ交談 微信洽談

產(chǎn)品詳情

中文名稱:APP抗體英文名稱:Mouse Monoclonal APP Antibody
品牌: 艾普蒂產(chǎn)地: 武漢
保存條件: Stored at -20°C for 672 year. Avoid repeated freeze / thaw cycles.產(chǎn)品類別: 抗體
重組: 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA
種屬反應(yīng)性: Human,Mouse,Rat 宿主: Mouse
偶聯(lián)物: 無(wú)靶點(diǎn): APP
2025-05-10 APP抗體 Mouse Monoclonal APP Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武漢 Stored at -20°C for 672 year. Avoid repeated freeze / thaw cycles. 抗體

驗(yàn)證與應(yīng)用

應(yīng)用及物種
WB咨詢技術(shù) Human,Mouse,Rat
IF咨詢技術(shù) Human,Mouse,Rat
IHC咨詢技術(shù) Human,Mouse,Rat
ICC1/200 - 1/1000 Human,Mouse,Rat
FCM咨詢技術(shù) Human,Mouse,Rat
Elisa1/10000 Human,Mouse,Rat
   

產(chǎn)品詳情

AliasesAAA; AD1; PN2; ABPP; APPI; CVAP; ABETA; PN-II; CTFgamma
Entrez GeneID351
clone3F12F6
WB Predicted band size87kDa
Host/IsotypeMouse IgG1
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenPurified recombinant fragment of human APP (AA: 483-699) expressed in E. Coli.
FormulationPurified antibody in PBS with 0.05% sodium azide.

+ +

  •  

     

       Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    


  •  

     

       Immunofluorescence analysis of A431 cells using APP mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    


           

參考文獻(xiàn)

以下是關(guān)于APP抗體的3篇代表性文獻(xiàn)摘要簡(jiǎn)述:

---

1. **文獻(xiàn)名稱**:Amyloid-β Immunotherapy for Alzheimer’s Disease

**作者**:Schenk, D., et al.

**摘要**:探討抗Aβ抗體通過(guò)激活小膠質(zhì)細(xì)胞清除腦內(nèi)淀粉樣斑塊的機(jī)制,動(dòng)物實(shí)驗(yàn)顯示免疫療法可減少轉(zhuǎn)基因小鼠的病理沉積,為阿爾茨海默病治療提供新方向。

---

2. **文獻(xiàn)名稱**:Targeting Amyloid-β Oligomers by Passive Immunization

**作者**:Sharman, M.J., et al.

**摘要**:研究發(fā)現(xiàn)針對(duì)APP不同表位的單克隆抗體(如6E10、4G8)對(duì)Aβ寡聚體清除效果差異顯著,部分抗體可改善模型動(dòng)物認(rèn)知功能,提示表位特異性影響治療效果。

---

3. **文獻(xiàn)名稱**:Passive Immunotherapy Against Aβ in APP Transgenic Mice

**作者**:Lemere, C.A., et al.

**摘要**:通過(guò)向APP/PS1轉(zhuǎn)基因小鼠注射抗APP抗體,發(fā)現(xiàn)其能穿透血腦屏障并減少可溶性Aβ40/42水平,延緩神經(jīng)突觸損傷,支持被動(dòng)免疫治療的臨床潛力。

---

如需具體文獻(xiàn)年份或補(bǔ)充其他研究(如臨床抗體藥物aducanumab相關(guān)論文),可進(jìn)一步調(diào)整。

       

背景信息

APP (amyloid precursor protein) is a transmembrane glycoprotein highly expressed in the brain and involved in synaptic formation, neuronal plasticity, and intracellular signaling. Its proteolytic processing through amyloidogenic or non-amyloidogenic pathways plays a central role in Alzheimer’s disease (AD) pathogenesis. In the amyloidogenic pathway, sequential cleavage by β-secretase (BACE1) and γ-secretase generates neurotoxic amyloid-beta (Aβ) peptides, which aggregate into plaques—a hallmark of AD. APP-targeting antibodies have emerged as critical tools for both research and therapeutic exploration.

Research-grade APP antibodies are widely used to detect APP expression, localization, and processing in cellular and animal models (e.g., transgenic mice), as well as in human biofluids like cerebrospinal fluid (CSF). These antibodies often target specific APP epitopes (e.g., N-terminal, C-terminal, or Aβ domains) to distinguish full-length APP from its proteolytic fragments (e.g., sAPPα, sAPPβ, Aβ). Therapeutically, anti-Aβ antibodies (e.g., aducanumab, lecanemab) aim to clear Aβ plaques or neutralize soluble Aβ oligomers, with some achieving clinical approval despite ongoing debates over efficacy and safety. Other strategies include BACE1 inhibitors or antibodies targeting APP cleavage sites to modulate Aβ production. Challenges remain in optimizing blood-brain barrier penetration, minimizing off-target effects, and addressing the complex pathophysiology of AD beyond Aβ-centric approaches. APP antibodies thus represent a dual-purpose innovation, bridging mechanistic studies and therapeutic development in neurodegenerative research.

       
關(guān)鍵字: APP抗體;APP;APP Antibody;

公司簡(jiǎn)介

湖北瑞和寧生物科技有限公司研究創(chuàng)新能力, 擁有完整、科學(xué)、質(zhì)量管理體系。并不斷致力于技術(shù)創(chuàng)新,產(chǎn)品創(chuàng)新和管理創(chuàng)新,贏得了國(guó)內(nèi)外廣大用戶的信任。
成立日期 2024-06-24 (2年) 注冊(cè)資本 50萬(wàn)(元)
員工人數(shù) 1-10人 年?duì)I業(yè)額 ¥ 100萬(wàn)以內(nèi)
主營(yíng)行業(yè) 中間體,化學(xué)試劑 經(jīng)營(yíng)模式 貿(mào)易,工廠,試劑,定制,服務(wù)
  • 湖北瑞和寧生物科技有限公司
VIP 1年
  • 公司成立:2年
  • 注冊(cè)資本:50萬(wàn)(元)
  • 企業(yè)類型:有限責(zé)任公司(自然人投資或控股)
  • 主營(yíng)產(chǎn)品:中間體。試劑
  • 公司地址:江漢區(qū)
詢盤

店內(nèi)推薦

ITGA6抗體 詢價(jià)
MAGEA3抗體 詢價(jià)
SEL1L抗體 詢價(jià)

APP抗體相關(guān)廠家報(bào)價(jià)

產(chǎn)品名稱 價(jià)格   公司名稱 報(bào)價(jià)日期
¥948
妙通(上海)生物科技有限公司
2025-07-18
詢價(jià)
上海妍琦生物科技有限公司
2025-07-18
¥265
上海鈺博生物科技有限公司
2025-07-18
¥5301.45
北京孚博生物科技有限公司
2025-07-17
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價(jià)格指該商品的參考價(jià)格,并非原價(jià),該價(jià)格可能隨著市場(chǎng)變化,或是由于您購(gòu)買數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價(jià)格,請(qǐng)咨詢商家,以實(shí)際成交價(jià)格為準(zhǔn)。請(qǐng)意識(shí)到互聯(lián)網(wǎng)交易中的風(fēng)險(xiǎn)是客觀存在的
主頁(yè) | 企業(yè)會(huì)員服務(wù) | 廣告業(yè)務(wù) | 聯(lián)系我們 | 舊版入口 | 中文MSDS | CAS Index | 常用化學(xué)品CAS列表 | 化工產(chǎn)品目錄 | 新產(chǎn)品列表 |投訴中心
Copyright ? 2008 ChemicalBook 京ICP備07040585號(hào)  京公海網(wǎng)安備110108000080號(hào)  All rights reserved.